RARG and cancer: Clinical recommendations by Aminkeng et al. (2016) suggest pharmacogenomic testing for RARG rs2229774, SLC28A3 rs7853758 and UGT1A6 rs17863783 variants in childhood cancer patients indicated for doxorubicin or daunorubicin treatment.